The company reported its first full year of profitability, driven by strong commercial performance of its key product. It also expanded its portfolio through a strategic acquisition, adding a late-stage therapy and an approved pediatric asset. This has reshaped its core franchise and marked a new phase for the business. Investor sentiment was notably positive, with the stock surging over 10% in a single day following the profit announcement.